ARNTL

Across TCGA pan-cancer cohorts, ARNTL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARNTL data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARNTL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARNTL expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where ARNTL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.316	0.881	.002	35	view →
UCEC	OS	Quartile	All	1.000	0.789	.011	14	view →
CCRCC	DFS	Quartile	All	0.932	0.567	.025	8	view →
LSCC	DFS	Tertile	II,III,IV	0.525	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARNTL–LUAD (DFS)

Open the LUAD breakdown →